Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: Reality, hope or myth?

Journal of Endocrinological Investigation

Volumn 33, Issue 8, 2010, Pages 576-578

  Pacini, F ^a   Cantara, S ^a   Capezzone, M ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Cytology; Fine needle aspiration; Oncogenes; Thyroid cancer; Thyroid nodule

Indexed keywords

TUMOR MARKER;

ASPIRATION BIOPSY; CYTOLOGY; DIAGNOSTIC PROCEDURE; GENE MUTATION; HUMAN; NOTE; THYROID CANCER; THYROID NODULE; THYROIDECTOMY;

EID: 78049389361     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346651     Document Type: Note

References (23)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295: 2164-7.
2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19: 1167-214.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154: 1-18.
4. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008, 36: 425-37.
5. Goldstein RE, Netterville JL, Burkey B, Johnson JE. Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg 2002, 235: 656-62.
6. Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol 2006, 34: 330-4.
7. Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal Markers of Thyroid Malignancies: Galectin-3, HBME-1, and Cytokeratin-19. Endocr Pathol 2010, Mar 3 [Epub ahead of print]; doi: 10.1007/s12022-010-9114-y.
8. Bartolazzi A, Orlandi F, Saggiorato E, et al; Italian Thyroid Cancer Study Group (ITCSG). Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 2008, 9: 543-9.
9. Saleh HA, Feng J, Tabassum F, Al-Zohaili O, Husain M, Giorgadze T. Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal 2009, 6: 18.
10. Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 2005, 12: 305-17.
11. Liou MJ, Chan EC, Lin JD, Liu FH, Chao TC. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Lett 2003, 10: 223-7.
12. Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in Fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004, 10: 2761-5. (Pubitemid 38509152)
13. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004, 89: 2867-72.
14. Marchetti I, Lessi F, Mazzanti CM, et al. Morpho-molecular diagnosis of papillary thyroid carcinoma: BRAFV600E detection a san important tool in preoperative evaluation of fine needle aspirates. Thyroid 2009, 19: 837-42.
15. Chung KW, Yang SK, Lee GK, et al. Detection of BRAF (V600E) mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF (V600E) mutation-prevalent area. Clin Endocrinol (Oxf) 2006, 65: 660-6.
16. Sapio MR, Guerra A, Posca D, et al. Combined analysis of galectin-3 and BRAF V600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 2007, 14: 1089-97.
17. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89: 5175-80. (Pubitemid 39391466)
18. Pizzolanti G, Russo L, Richiusa P, et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 2007, 17: 1109-15.
19. Domingues R, Mendonça E, Sobrinho L, Bugalho MJ. Searching for RET/PTC rearrangement and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 2005, 16: 27-31.
20. Sapio MR, Posca D, Raggioli A, et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol 2007, 66: 678-83.
21. Nikrforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009, 94: 2092-8.
22. Cantara S, Capezzone M, Marchisotta S, et al. Impact of protooncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. Clin Endocrinol Metab 2010, 95: 1365-9.
23. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol 2010, 118: 17-23.